President John Saharek on the ImprimisRx pipeline, details 3 products
ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times Europe's David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting, including:
- Moxi-Brom (moxifloxacin hydrochloride 0.5% and bromfenac sodium sesquihydrate 0.075%)
- Klarity-CL drops (cyclosporine 0.1% / loteprednol etabonate 0.2% ophthalmic suspension)
- Tim-Brim-Dor-Bim (prednisolone acetate 1%, gatifloxacin 0.5%, bromfenac 0.075%).
The American Academy of Ophthalmology (AAO) annual meeting was held November 12 to 15 at the Ernest N. Morial Convention Centre in New Orleans, Louisiana, United States. The event included Subspecialty Days and a virtual component for remote participation.
Related Content: Additional AAO content | Retina | Inflammation & Infection
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
